Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afeletecan in Recurrent or Metastatic Renal Cell Carcinoma
NCT00040989Phase 2Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afeletecan in renal cell carcinoma (RCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Status: withdrawn.
02
Drugs
afeletecan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00040989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040989.